Dividend Kings are unquestionably among the top picks for income-seeking investors. These are companies that have increased their payouts for at least 50 consecutive years, which strongly suggests they have resilient businesses and can generate consistent profits and cash flow.

Many Dividend Kings are worth investing in, but let's discuss just two today: Abbott Laboratories (NYSE: ABT) and Johnson Johnson (NYSE: JNJ). These leaders in healthcare have been rewarding shareholders for decades and should continue to do so for a long time. Here is why.

At first glance, Abbott Laboratories doesn't seem to be doing well right now. In 2023, the company's sales declined by 8.1% to about $40.1 billion. Adjusted net earnings per share (EPS) came in at $4.44, down from the $5.34 reported in the previous fiscal year.

Continue reading

Source Fool.com